Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.

Recently, studies on dendritic cell (DC) vaccine have focused on the development of more effective DC vaccine regimen, such as the application of multiple tumor-associated antigen-targeted DC vaccine. This approach could be used to enhance efficacy of DC-based vaccine against tumors and infectious diseases. In this study, we analyzed whether DC from patients with hepatocellular carcinoma can be infected with the alpha-fetoprotein (AFP) gene and/or HBsAg gene (hepatocellular carcinoma-related antigen).

[FK228 promotes the IL-3 mediated proliferation and differentiation of human erythroid progenitor cells].

Aim: To investigate the role of histone deacetylases (HDACs) inhibitor FK228 in the IL-3 mediated proliferation and differentiation of human erythroid progenitor cells.

Methods: CD34(+) cells were separated from the granulocyte colony-stimulating factor(G-CSF)-mobilized peripheral blood of cancer patients and cultured for 7 days with FK228 of different concentrations, stem cell factor(SCF) and interleukin 3 (IL-3) in serum-free medium. Flow cytometry was performed to analyze the expression of CD14, GPA, CD15 and CD36 on the cells and the colony assay of erythroid cells was conducted.

[Effect of Notch ligand Delta-1 on the differentiation and maturation of erythroid progenitors in humans].

Objective: To explore the biological effect of Notch ligand Delta-1 (Notch L delta-1) on the sIL-6R during the differentiation of erythroid hematopoiesis.

Methods: Mononuclear cells (MNCs) was isolated from the normal cord blood using Ficoll graduation solution. MNCs were enriched for CD34(+) CD38(-) cells by CD34 immunomagnetic beads and a FACS Vantage.

[EPO mediated proliferation and differentiation of human erythroid progenitor inhibited by FK228].

Aim: To investigate the function of histone deacetylases (HDACs) inhibitor FK228 in the EPO mediated proliferation and differentiation of human erythroid progenitor.

Methods: CD34(+) cells were separated from the granulocyte colony-stimulating factor-mobilized peripheral blood of patients with cancer. They were cultured for 7 days with serum-free medium containing stem cell factor (SCF), erythropoietin (EPO) or SCF+IL-3 in the presence of escalated dosages of FK228.

Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies.

Aim: To compare the effect, adverse events, cost-effectiveness and dose intensity (DI) of oral Xeloda vs calcium folinate (CF)/5-FU combination chemotherapy in patients with advanced gastrointestinal malignancies, both combined with bi-platinu two-way chemotherapy.

Methods: A total of 131 patients were enrolled and randomly selected to receive either oral Xeloda (X group) or CF/5-FU (control group). Oral Xeloda 1,000 mg/m2 was administered twice daily from d 1 to 14 in X group, while CF 200 mg/m2 was taken as a 2-h intravenous infusion followed by 5-FU 600 mg/m2 intravenously for 4-6 h on d 1-5 in control group.

Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer.

Aim: To develop an oral attenuated Salmonella typhimurium vaccine against gastric cancer and to evaluate its efficacy in mice.

Methods: A complementary sequence of Nco I site and a sequence coding for MG7-Ag mimotope were designed at the 5' terminus of forward primer. Using p1.

[Screening of bioactive peptide that mimic the epitope of gastric cancer associated antigen].

Aim: To screen bioactive peptides that mimic the epitope of gastric cancer associated antigen.

Methods: Anti-gastric cancer monoclonal antibody (mAb) MG7 was purified by ion chromatography, and then coated on ELISA plate. By using the mAb as selective molecular, a 12-meres phage displaying peptide library was biopanned, and the positive clones were selected.

Development of an oral DNA vaccine against MG7-Ag of gastric cancer using attenuated salmonella typhimurium as carrier.

Aim: To develop an oral DNA vaccine against gastric cancer and evaluate its efficacy in mice.

Methods: The genes of the MG7-Ag mimotope and a universal Th epitope (Pan-DR epitope, PADRE) were included in the PCR primers. By PCR, the fusion gene of the two epitopes was amplified.

Expression and bioactivity identification of soluble MG7 scFv.

Aim: To examine the molecular mass and identify the bioactivity of MG7 scFv for its application as a targeting mediator in gene therapy of gastric cancer.

Methods: Two strongly positive recombinant phage clones screened from MG7 recombinant phage antibody library were separately transfected into E.coli TG1.

Down-regulation of Hsp90 could change cell cycle distribution and increase drug sensitivity of tumor cells.

AIM:To construct Hsp90 antisense RNA eukaryotic expression vector, transfect it into SGC7901 and SGC7901/VCR of MDR-type human gastric cancer cell lines, HCC7402 of human hepatic cancer and Ec109 of human esophageal cancer cell lines, and to study the cell cycle distribution of the gene transected cells and their response to chemotherapeutic drugs.METHODS:A 1.03kb cDNA sequence of Hsp90beta was obtained from the primary plasmid phHSP90 by EcoR I and BamH I nuclease digestion and was cloned to the EcoR I and BamH I site of the pcDNA by T4DNA ligase and an antisense orientation of Hsp90beta expression vector was constructed.